September 22, 2009 (FinancialWire) — Ingen Technologies, Inc. (OTC: IGNT) the Medical Device Manufacturer of the new Oxyview Nasal Cannula focused in the $8 billion global Respiratory Markets for the growing Chronic Obstructive Pulmonary Disease aging population and emerging markets for Home, Hospital and Aviation Industries, announced that Charles E. Vorwaller has accepted a position on the board of directors, and Donna Murtaugh has accepted a position on Ingen’s Medical advisory board.

Charles E. Vorwaller, based in Parker, Colorado is a 25-year veteran in sales and management in the healthcare industry, and has been recognized as a strategic planner and visionary in multiple market segments. Currently he is the president of National Sales Networks, Inc. a sales and marketing consulting company. Since 2006, he has served as the director of Business Development for Litecure, LLC; a worldwide developer, manufacturer, and marketer of medical devices and products used in a broad range of interventional medical specialties. He held several senior positions, including vice president Sales and National Account Manager at both publicly traded and privately held medical companies, including Access Battery, Inc.; and Rocky Mountain Medical Corp.. Charles holds a Bachelor Degree in Marketing and a Bachelor Degree in Management from Westminster College. He has been actively involved for over 10 years in the Boy Scouts of America; as well as coaching youth basketball and soccer. He and his wife have been married 27 years, and have five children.

Donna Murtaugh, based in Glenolden, Pennsylvania has been a practicing Registered Nurse for more than 10 years and is a licensed Nurse Practitioner in the State of Pennsylvania. She is an active member of the American Academy of Nurse Practitioners, a member of Sigma Theta Tau International Nursing Honor Society and the Association of Clinical Research Professionals. She is the co-founder of Wellspring Clinical Resources located in Wallingford, Pennsylvania, where she works with major pharmaceutical firms under FDA/GCP compliance for drug research. Donna is a Nurse Practitioner per diem with Thomas Jefferson Hospital in Philadelphia, Pennsylvania.

Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.